News

New Horizons For Measles-Based Vaccines And Therapies

Vienna (Austria), 15 September 2016 – Social Event and
Pre-Symposium Dinner, 14 September
Starting at 16:00

AGENDA

TOPIC 1

Setting the stage:
Viral vectors and global challenges

9:00 - 9:20: Christian Mandl
"History of Viral Vectors - current opportunities and challenges"

9:20 - 9:50: Scott Weaver
"Emerging Viral Infections: West Nile, Chikungunya, Zika ... how can we prepare?"

9:50 - 10:20 Erich Tauber
"Rapid development of new vaccines against Chikungunya and Zika using measles vaccine vectors"


Coffee Break (20 min)


TOPIC 2

Molecular biology and host immune response:
challenges, opportunities and new insights

10:40 - 11:10: Frederic Tangy
"History of measles vector and discovery of its utility in human vaccination"

11:10 - 11:40: Diane Griffin
"Persistence of measles virus RNA and vaccine boosting of immune responses in nonhuman primates and humans"

11:40 - 12:10: Roberto Cattaneo
"Structural and functional determinants of measles virus tropism"


Lunch Break (1 hr)


TOPIC 3

Rapid Response and Emerging infections
The roles of Big Pharma, Biotech, Public and Private Funders

13:10 - 14:00: Podium Discussion


Coffee Break (30 min)


TOPIC 4

Measles vectors as a broad platform

14:30 - 15:00: Michael Muehlebach
"Exploring novel vaccine targets"

15:00 - 15:30: Steve Russell
"Preclinical and clinical experience with oncolytic measles approaches"


TOPIC 5

Translation of Basic Research into
Clinical Vaccine Candidates
The roles of Academia, Biotech, Big Pharma and Funders

15:30 - 16:30 Podium Discussion


MEETING CONCLUSION

16:30 - 16:45: Gerd Zettlmeissl
"Conclusions and Farewell"

Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK

more

Chikungunya-Fever: Themis Bioscience Starts Phase II Clinical Study in Endemic Area

more

NIH and Themis Bioscience Announce the Initiation of a Clinical Trial of a Chikungunya Vaccine

more

Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine

more

Zika Virus: Top EU-Groups Join Forces in Quest for Vaccine. Themis Measles Vector Technology Central to Action Plan

more

Themis Bioscience Successfully Closes 10 M EUR Financing Round

more

Zika Vaccine Development Receives Big Boost by Innovate UK

more

Interview W24/Zika

more

New worldwide, exclusive license agreement provides broad access to Institut Pasteur's virus vector technology – Zika vaccine development progressing with high priority.

more

Two renowned Vaccine Experts Joining Themis Bioscience GmbH

more

Themis Bioscience’s Raises up to EUR 10 Million in Series B New Board to drive partnerships and commercialization of product pipeline

more